These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21382992)

  • 21. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
    Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
    J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bevacizumab and arterial hypertension or proteinuria: management].
    Senellart H; Bennouna J
    Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.
    Smith AR; Hennessy JM; Kurth MA; Nelson SC
    Pediatr Blood Cancer; 2008 Sep; 51(3):418-20. PubMed ID: 18493993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
    Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
    Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].
    Mazières J; Dansin E
    Rev Pneumol Clin; 2008 Aug; 64(4):166-72. PubMed ID: 19019283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
    Tanvetyanon T; Murtagh R; Bepler G
    J Thorac Oncol; 2009 Feb; 4(2):268-9. PubMed ID: 19179909
    [No Abstract]   [Full Text] [Related]  

  • 35. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
    Pereg D; Lishner M
    Eur Heart J; 2008 Oct; 29(19):2325-6. PubMed ID: 18762551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C
    Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
    Riess JW; Logan AC; Krupitskaya Y; Padda S; Clément-Duchêne C; Ganjoo K; Colevas AD; Pedro-Salcedo MS; Kuo CJ; Wakelee HA
    Cancer Invest; 2012 Mar; 30(3):231-5. PubMed ID: 22360362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraneoplastic polymyositis associated with crescentic glomerulonephritis.
    Chiu KC; Tsai TC; Lin WT; Lee WJ; Su CC; Chen CY
    Ren Fail; 2008; 30(9):939-42. PubMed ID: 18925535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrotic syndrome after bevacizumab: case report and literature review.
    George BA; Zhou XJ; Toto R
    Am J Kidney Dis; 2007 Feb; 49(2):e23-9. PubMed ID: 17261417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.